The results of Redwood Pharma’s Phase II study of RP101 have now been published in the medical journal Advances in... View Article
Redwood Pharma AB’s (“Redwood Pharma” or “the Company”) new issue of shares with preferential rights for shareholders (the “Rights Issue”)... View Article
Redwood Pharma AB (publ) (“Redwood Pharma” or “the Company”) has arranged information presentations in connection with the Company’s rights issue with a subscription period 25... View Article
The Board of Directors of Redwood Pharma AB (publ) (“Redwood Pharma” or “the Company”) today announces its intention to switch stock exchanges from... View Article
RP101 demonstrates treatment difference versus control (Intelligel vehicle) in inferior corneal staining with robust and significant improvement SANDE symptom score... View Article